|
|
AGALSIDASE BETA
Resources
MedlinePlus Drug Information: Agalsidase beta (Systemic): Agalsidase beta is available only with your doctor's prescription, in the following dosage ... For agalsidase beta, the following should be considered: http://www.nlm.nih.gov/medlineplus/druginfo/drug_Fa.html MedlinePlus Drug Information: Drugs beginning with F: USP DI - Agalsidase beta (Systemic); Factive USP DI - Gemifloxacin (Systemic); Factive® MedMaster - Gemifloxacin; factor 7 http://www.fda.gov/cder/biologics/products/agalgen042403.htm Agalsidase beta - Product Approval Information - Licensing Action: Agalsidase beta - Product Approval Information - Licensing Action. http://www.cms.hhs.gov/mcd/index_local_alpha.asp?from=alphaarticle&letter=F Centers for Medicare & Medicaid Services: ...view detailsA17860, Fabrazyme (agalsidase beta). view detailsA15334, Fabrazyme® (agalsidase beta) - New FDA Indications http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12968124&dopt=Abstract Agalsidase beta (Fabrazyme) for Fabry disease.: Agalsidase beta (Fabrazyme) for Fabry disease. [No authors listed] MeSH Terms Chills/chemically induced Dose-Response Relationship, Drug http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15086478&dopt=Abstract Enzyme replacement therapy with agalsidase beta in kidney ...: Fabry myocardiopathy received the rh-alpha-Gal A, agalsidase beta, ... Our pilot study provides preliminary evidence that ERT with agalsidase beta, http://www.clinicaltrials.gov/ct/show/NCT00081497 Clinical Trial: A Study of the Safety and Efficacy of Fabrazyme in ...: Condition, Treatment or Intervention, Phase. Fabry Disease, Drug: Fabrazyme (agalsidase beta), Phase IV. MedlinePlus related topics: Genetic Brain http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=F Drugs@FDA: FABRAZYME (AGALSIDASE BETA); FACTIVE (GEMIFLOXACIN MESYLATE); FACTREL (GONADORELIN HYDROCHLORIDE); FAMOTIDINE (FAMOTIDINE); FAMOTIDINE PRESERVATIVE FREE http://www.visn21.med.va.gov/show.asp?durki=1010&site=29&return=817 Welcome to the VA Sierra Pacific Network (VISN 21): Agalsidase beta (Fabrazyme) Injection Alpha-Adrenergic Blockers (Uroselective/Non-formulary) Alemtuzumab (Campath) Amiodarone Injection http://edocket.access.gpo.gov/2004/03-32322.htm FR Doc 03-32322: 9208 Injection, IV, Agalsidase beta, 123.78 18.50 per 1 mg. C9209.............................. 9209 Injection, IV, Laronidase, per 2.9 644.10 96.28 mg. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=12471562 Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing ...: Agalsidase a is obtained from human fibroblasts that have been modified by ... deficiency: a new disorder of mitochondrial fatty acid beta -oxidation. http://www.dhfs.wisconsin.gov/medicaid4/maxfees/txt/maxfee15_physician_8.txt 93543 INJECTION PROCEDURE DURING CARDIAC CATHETERIZATION; 93543 19 ...: EPINEPHRIN, UP TO 1 ML AMPUL J0170 19 20 21 22 45 88 270 10/01/03 4.00 4.00 J0180 INJECTION, AGALSIDASE BETA, 1 MG J0180 19 20 21 22 45 88 21J 01/01/05 http://molbio.info.nih.gov/cgi-bin/moldraw?1R47 Academic resources: http://pharmacy.isu.edu/~hurley/seminar/semsched_2003.htm Senior Seminar 2003: 11/28. . . Thanksgiving, . . 12/5. 3 PM. Joni, Waldram, Fish Ly. The role of agalsidase beta (Fabrazyme®) in the treatment of Fabry disease. . 4 PM. ... http://www.oncolink.upenn.edu/resources/article.cfm?c=3&s=8&ss=23&id=9609&month=04&year=2003 Cancer Resources—Cancer News, Cancer Conferences, Cancer Causes ...: Genzyme had been trying for years to get its drug, called Fabrazyme (agalsidase beta), on to the US market before rival Transkaryotic Therapies Inc.'s (TKT ... http://www.oncolink.upenn.edu/resources/article.cfm?c=3&s=8&ss=23&Year=2003&Month=1&id=9262 Cancer Resources—Cancer News, Cancer Conferences, Cancer Causes ...: FDA) advisors voted 14-1 Monday that positive results with a surrogate endpoint in studies of Genzyme's Fabrazyme (agalsidase beta) were "reasonably likely" to ... http://www.journals.uchicago.edu/cgi-bin/resolve?id=doi:10.1086/422366 Wilcox et al., Long-Term ERT for Fabry Disease: ...controlled study received subsequently 1 mg/kg of rh- GalA (agalsidase beta, Fabrazyme, Genzyme Corporation) biweekly in an ongoing open-label extension study. ... http://www.journals.uchicago.edu/cgi-bin/resolve?id=doi:10.1086/318809 Eng et al., Enzyme Replacement in Fabry Disease: ...with Fabry disease were recruited for this multidose, open-label, single-center, dose-escalation study of rh GalA (Fabrazyme [agalsidase beta]; Genzyme). ... http://www.wwu.edu/depts/healthyliving/PE511info/cancer/My%20Cancer%20Webs/journals_articles_1.htm Journals Articles 1: The 28 new therapeutic agents marketed in the United States during 2003 are reviewed in this article: adalimumab, agalsidase beta, alefacept, alfuzosin ... http://www.baylorhealth.edu/HealthNews/reuters/NewsStory0425200329.htm FDA approves first drug for Fabry disease: Fabrazyme (agalsidase beta) is a recombinant, or laboratory-produced, version of a natural human enzyme that is lacking in people with Fabry disease. ... https://www.med.miami.edu/patients/glossary/art.asp?articlekey=7558 University of Miami School of Medicine - Glossary - Disease, Fabry: European Union granted orphan drug status to two forms of recombinant galactosidase A -- Replagal (agalsidase alfa) and Fabrazyme (agalsidase beta) -- for long ... http://0-www.nlm.nih.gov.csulib.ctstateu.edu/medlineplus/druginfo/drug_Fa.html Drug ingredients index Search the web for more on AGALSIDASE BETA : Mongabay Home | Rainforests | Madagascar | Contact ] © 2006 Rhett A. Butler. |
|
Copyright Rhett A. Butler 2006 |
